MAPT rs17651213 — The Splice Regulator at the Core of Tau Isoform Balance
Within the MAPT gene on chromosome 17, the rs17651213 variant sits in a functionally critical position:
it is one of just two intronic polymorphisms that directly control how much tau protein includes its
N-terminal exon 3 domain. While the broader H1/H2 haplotype distinction at MAPT has been recognized
as a major neurodegenerative disease risk factor for decades, rs17651213 was identified in a landmark
2017 study as one of the molecular levers behind that risk — not merely a passive haplotype marker.
The MAPT gene produces tau, the microtubule-stabilizing protein whose aggregation into neurofibrillary
tangles defines a family of neurodegenerative diseases called tauopathies. What makes tau biology
especially complex is that the gene produces multiple isoforms through alternative splicing, and the
balance between those isoforms — particularly the ratio of 3-repeat (3R) to 4-repeat (4R) tau — differs
between healthy brains and diseased ones. The H1 haplotype, tagged by rs17651213's G allele, is
consistently found in approximately 94% of progressive supranuclear palsy (PSP) patients compared
to about 64% of the general population.
The Mechanism: hnRNP F/Q and Exon 3 Inclusion
A 2017 mechanistic study used whole-locus MAPT genomic DNA vectors to dissect the contribution of
individual intronic variants to haplotype-specific tau splicing | The study expressed H1 and H2
haplotypes with selective allele swaps at rs17651213 and rs1800547 to isolate each variant's
contribution, then identified binding proteins by RNA-protein pull-down and mass spectrometry.
The researchers identified that both rs17651213 and its partner rs1800547 create distinct
RNA-protein binding patterns for two splicing factors: hnRNP F and hnRNP Q.
Crucially, when rs17651213 was swapped alone between haplotype backgrounds — placing the H2 (A) allele
into an H1 context — exon 3 inclusion increased 2.52-fold. This makes rs17651213 the dominant driver
of the two-SNP regulatory pair: it accounts for more of the exon 3 splicing difference between H1 and
H2 than rs1800547 does individually. Overall, the H2 haplotype produces 1.76-fold more exon 3-containing
tau transcripts than H1, and knockdown experiments confirmed that hnRNP F and hnRNP Q actively promote
H1:H2 differential splicing — reducing both factors increased the H1:H2 exon 3 ratio, while the
effects were allele-specific at rs17651213 and rs1800547.
Exon 3 encodes a region of tau's N-terminal projection domain involved in membrane interactions and
cytoskeletal attachment. The H1-driven reduction in exon 3 inclusion shifts tau isoform composition
toward higher 4-repeat (4R) forms, which are the main tau species in pathological aggregates in PSP
and corticobasal degeneration (CBD). This mechanistic connection directly links the rs17651213 G allele
to the molecular basis of 4R tauopathy susceptibility.
The Evidence for Parkinson's Disease and PSP
A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes —
defined using haplotype-tagging variants including rs17651213 — had an odds ratio of 1.46 (95% CI
1.25–1.69, p=8×10⁻⁷) for Parkinson's disease | The association was consistent across familial and
sporadic disease, both sexes, and early- and late-onset subgroups.
For PSP, a meta-analysis of 82 case-control studies found H1 haplotype carriers have an odds ratio
of 1.96 for PSP and 2.51 for CBD | The most risk-elevated configurations are H1 sub-haplotypes H1d
and H1g, which appear to compound the exon 3 splicing shift through additional cis-regulatory
variants. H1/H1 homozygotes at rs17651213 are found in
approximately 94% of neuropathologically confirmed PSP cases.
Alzheimer's Disease: A Tau-Driven Pathway
A study of 17,996 participants found the H1 haplotype independently associated with Alzheimer's
disease risk (OR 1.12, p=0.0025), with the strongest effect in APOE ε4 non-carriers over age 77 |
This suggests that H1-driven tau isoform imbalance represents a distinct, slower causal pathway to
AD that is less dependent on amyloid accumulation than the APOE ε4 pathway.
For people without APOE ε4, the rs17651213 G/G genotype may be a more prominent contributor to
late-life cognitive decline.
Practical Actions
The rs17651213 G/G genotype identifies the same population-level risk as H1/H1 status at rs1800547,
since both SNPs co-define the H1 haplotype and are in very strong linkage disequilibrium. The key
difference is that rs17651213 has been shown to be a functional driver — not just a tag — of the
splicing difference. The actionable implications focus on neurological monitoring and neuroprotective
lifestyle: awareness of early PSP/CBD features (distinct from typical Parkinson's disease) enables
accurate diagnosis, and head trauma prevention is especially relevant given that TBI may accelerate
tau pathology in H1/H1 individuals already producing tau isoforms skewed toward 4R-prone forms.
Interactions
rs17651213 and rs1800547 work as a mechanistic pair — both must be considered together to fully
understand H1-versus-H2 exon 3 splicing differences. They are in very strong LD, so most H1/H1
individuals at rs17651213 will also be H1/H1 at rs1800547 and vice versa. The H1c sub-haplotype
tagged by rs242557 adds further risk on top of the baseline H1 genotype. In Alzheimer's disease,
the H1/H2 effect interacts with APOE genotype (rs429358), with H1 risk concentrated specifically
in APOE ε4 non-carriers.
All Genotypes
One H1 allele, one protective H2 allele — intermediate tauopathy risk with partial exon 3 splicing rescue
You carry one copy of the H1 allele (G) and one copy of the protective H2 allele (A) at this MAPT splice-regulatory variant. This heterozygous genotype is found in approximately 32% of people of European descent. Your risk for Parkinson's disease, PSP, and corticobasal degeneration is intermediate — meaningfully lower than H1/H1 but not as low as H2/H2. Having one H2 (A) allele partially rescues exon 3 inclusion: your tau transcripts come from both haplotype backgrounds, and the H2-driven splicing pattern contributes some fraction of the higher exon 3 inclusion that fully protects H2/H2 individuals. The magnitude of risk reduction from a single H2 allele is real but incomplete.
Two copies of the H1 splicing variant — reduced exon 3 inclusion, elevated 4R tau, and higher risk for PSP, Parkinson's, and Alzheimer's disease
You carry two copies of the H1 allele (G) at this MAPT splice-regulatory variant. This genotype is the ancestral and most common form, shared by approximately 64% of people of European descent. The GG genotype reduces inclusion of MAPT exon 3 in tau transcripts, shifting isoform balance toward 4-repeat (4R) tau — the predominant form found in pathological aggregates in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). H1/H1 confers an odds ratio of approximately 1.46 for Parkinson's disease and is found in approximately 94% of PSP patients (versus ~64% of the general population). The H1 haplotype also independently increases Alzheimer's disease risk (OR ~1.12), particularly in people who do not carry the APOE ε4 allele. Most people with this genotype will never develop these conditions — genetic risk is one of many contributors, and modifiable factors remain important.
Two copies of the protective H2 splicing allele — enhanced exon 3 inclusion, lower 4R tau, and substantially reduced risk for most tauopathies
You carry two copies of the protective H2 allele (A) at this MAPT splice-regulatory variant. The AA genotype is found in approximately 4% of people of European descent and is very rare in East Asian (<1%) and African (~4%) populations. The A allele at rs17651213 is the dominant driver of the H2 haplotype's higher exon 3 inclusion — it alone accounts for a 2.52-fold increase in exon 3-containing tau transcripts when placed into an H1 context. H2/H2 is associated with substantially reduced risk for Parkinson's disease, PSP, and corticobasal degeneration. H1/H1 carriers are found in approximately 94% of PSP patients, and H2/H2 individuals are correspondingly underrepresented in tauopathy case series. This genotype shifts tau isoform balance away from aggregation-prone 4R species.